Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece.
about
Cost-effectiveness of bortezomib for multiple myeloma: a systematic reviewWhen to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES.Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients.Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
P2860
Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Economic evaluation of therapi ...... ry multiple myeloma in Greece.
@ast
Economic evaluation of therapi ...... ry multiple myeloma in Greece.
@en
type
label
Economic evaluation of therapi ...... ry multiple myeloma in Greece.
@ast
Economic evaluation of therapi ...... ry multiple myeloma in Greece.
@en
prefLabel
Economic evaluation of therapi ...... ry multiple myeloma in Greece.
@ast
Economic evaluation of therapi ...... ry multiple myeloma in Greece.
@en
P2860
P356
P1476
Economic evaluation of therapi ...... ory multiple myeloma in Greece
@en
P2093
N Maniadakis
V Fragoulakis
P2860
P356
10.2147/CMAR.S43373
P407
P577
2013-04-10T00:00:00Z